# A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy

> **NCT07675811** · PHASE3 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 570 (estimated)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** REGN-2Cat
- **DRUG:** Freneslerbart
- **DRUG:** Mevonlerbart
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07675811
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2029-05-31
- **Final completion:** 2029-09-20
- **Target enrollment:** 570 (ESTIMATED)
- **Last updated:** 2026-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07675811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07675811, "A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07675811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*